Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

Fate Therapeutics (FATE) Misses Q3 EPS by 2c

November 5, 2019 5:11 PM EST

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $1.79 million.

First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with RituximabReceived FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen... More